Antimicrobial activity of DC-159a, a new fluoroquinolone, against 1,149 recently collected clinical isolates
Jones, Ronald N.
Fritsche, Thomas R.
Sader, Helio S. [UNIFESP]
Is part ofAntimicrobial Agents and Chemotherapy
MetadataShow full item record
The activity of DC-159a, a novel orally administered fluorinated quinolone, was evaluated by reference broth microdilution or agar dilution methods against 1,149 recently collected clinical isolates from five continents. Against pathogens associated with community-acquired respiratory tract infections (CA-RTIs), the MIC(90)s were 0.12 mu g/ml for Streptococcus pneumoniae, 0.015 to 0.03 mu g/ml for Haemophilus influenzae, 0.03 mu g/ml for Moraxella catarrhalis, and 0.12 mu g/ml for beta-hemolytic streptococci. Similarly, DC-59a was potent against various types of staphylococci (MIC90 range, 0.03 to 2 mu g/ml), Enterococcus faecalis (MIC90, 4 mu g/ml), wild-type isolates of the family Enterobacteriaceae (MIC90 range, 0.06 to 2 mu g/ml), wild-type Pseudomonas aeruginosa (MIC90, 2 mu g/ml), and Acinetobacter spp. (MIC90, 0.12 mu g/ml). Fluoroquinolone-nonsusceptible organism subsets usually had elevated DC-159a MICs, but the MICs were often two- to fourfold lower than those of levofloxacin and moxifloxacin. in conclusion, DC-159a appears to possess a balanced broad spectrum of activity that exceeds the activities of the currently marketed fluoroquinolones, especially against pathogens that cause CA-RTIs.
CitationAntimicrobial Agents and Chemotherapy. Washington: Amer Soc Microbiology, v. 52, n. 10, p. 3763-3775, 2008.
SponsorshipDaiichi Pharmaceutical Co., Ltd.
- EPM - Artigos